NTT-Shochiku Partners Decides to Stream Exciting "Cho Kabuki" Performance to 11 Countries
TOKYO, Sept. 17, 2021 /PRNewswire/ -- NTT-Shochiku Partners has recorded live performances of the "Cho Kabuki" stage productions at the Minamiza Theatre in Kyoto for audiences to watch on demand. The live recordings took place on September 12 (Sun.) and the on-demand service will be available from 12:00 p.m. (JST), September 20 (Mon.), to 11:59 p.m. (JST), September 26 (Sun.), 2021. Tickets are available for purchase now.
Established in 2016, "Cho Kabuki" is a unique stage performance which combines kabuki, a form of traditional Japanese theater with a 400-year history, and cutting-edge ICT technology, including "Kirari!" (*), Ultra-realistic Communication Technology from Nippon Telegraph and Telephone Corporation ("NTT"). The show co-stars one of today's most popular kabuki performers, Nakamura Shido, alongside the world's biggest virtual diva, Hatsune Miku, who will play the role of a villain for the first time. (*) "Kirari!" ( https://group.ntt/en/magazine/blog/kirari/)
A voluntary association established by NTT and Shochiku Co. Through this partnership, NTT and Shochiku aim to realize a new entertainment business by developing the use of ICT in actual kabuki performances.
The on-demand program is arranged in the following way:
Introductory film - The Appeal of Cho Kabuki
Act 1 - MIYAKOZOME KABUKI NO IRODORI This new dance production will be shown for the first time ever. In the last scene, Hatsune Miku uses her long hair as part of the performance which is one of the highlights.
Act 2 - OTOGIZOSHI KOI NO SUGATAE This returns to the stage after its initial play at the Niconico Net Chokaigi, April 2021. Based on a traditional kabuki performance, it is a dramatic story and shows many beautiful places in Kyoto. Hatsune Miku plays the villain role and her performance and appearance is a mix of that of woman and spider. The last scene is a dramatic battle scene and is not to be missed.
Rubrik, Inc. today announced the pricing of its upsized initial public offering of 23,500,000 shares of its Class A common stock at a public offering price of $32.00 per share. In addition, Rubrik has granted the underwriters a 30-day option to...
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed,...
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...
The Board of Directors of TransAlta Corporation declared a quarterly dividend of $0.06 per common share payable on July 1, 2024 to shareholders of record at the close of business on June 1, 2024. The Board of Directors also declared the following...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...